Google Ventures Backs Adimab in Antibody Discovery Business
Summary
Adimab’s new relationship with Google Ventures gives the small firm, in addition to cash, an investor with deep knowledge of computer systems, which are a key component to the drug-discovery process.Adimab has previously forged research collaboration deals with U.S. pharma giant Merck & Co. and Swiss healthcare products powerhouse Roche.Gerngross has said the process of discovering an antibody with therapeutic potential takes about eight weeks, which is much faster than traditional methods of doing the same.“Adimab reviewed multiple investment proposals but it was clear that Google Ventures immediately understood our value proposition—that a prolific discovery platform can drive even greater productivity when integrated with advanced computational tools,” Errik Anderson, chief operating officer of Adimab, said in a statement.Further, computer tools could also be used to expedite the process of optimizing the effectiveness of antibodies in treating specific germs, which now takes about four months in the laboratory, according to Gerngross.
Classifications
AskAI Classifications
LabelsLinked Companies
